Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth

Gumbo, Tawanda; Louie, Arnold; Liu, Weiguo; Ambrose, Paul G.; Bhavnani, Sujata M.; Brown, David; Drusano, George L.
January 2007
Journal of Infectious Diseases;1/15/2007, Vol. 195 Issue 2, p194
Academic Journal
Background. It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth. We examined the veracity of this cornerstone belief. Methods. We used an in vitro infection model in which M. tuberculosis was exposed to isoniazid concentration- time profiles encountered in human patients. Experiments were performed to examine the time-related changes in the total bacterial population, the isoniazid-susceptible subpopulation, and the isoniazid-resistant subpopulation. Results. The cessation of microbial kill occurred between days 3 and 4 of isoniazid therapy, as occurs in patients. There were multiple logs of organisms in the exponential phase of growth remaining at the time when bactericidal activity ceased. The isoniazid-susceptible subpopulation was replaced by an isoniazid-resistant subpopulation after 80 h of therapy. The size of the isoniazid-susceptible subpopulation continued to decrease after the total population had ceased to decrease, whereas the resistant subpopulation remained in the exponential phase of growth. Resistance was due to single point mutations in the catalase-peroxidase gene and to reserpine-inhibitable efflux pumps. Conclusions. The age-old hypothesis that isoniazid's microbial killing of M. tuberculosis during log-phase growth ceases because of the depletion of this bacillary population needs to be modified.


Related Articles

  • Synthesis and Anti-Mycobacterial Activity of N'-[(E)-(Disubstituted- Phenyl)Methylidene]Isonicotino-Hydrazide Derivatives. Junior, Ivan N.; Lourençco, Maria C. S.; Henriques, Maria das Graças M. O.; Ferreira, Barbara; Vasconcelos, Thatyana R. A.; Peralta, Mônica A.; de Oliveira, Pedro S. M.; Wardell, Solange M. S. V.; de Souza, Marcus V. N. // Letters in Drug Design & Discovery;Nov2005, Vol. 2 Issue 7, p563 

    A series of eight N'-[(E)-(disubstituted-phenyl)methylidene]isonicotino-hydrazide derivatives were synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis, and the activity expressed as the minimum inhibitory concentration (MIC) in mg/mL. Four...

  • Combined drug medium with isoniazid and rifampicin for identification of multi-drug resistant Mycobacterium tuberculosis. Nalini, S.; Lakshmi, R.; Devika, K.; Ravikumar, D.; Ramachandran, R. // Indian Journal of Medical Microbiology;Apr2010, Vol. 28 Issue 2, p162 

    A low-cost method of detecting multi-drug resistant Mycobacterium tuberculosis (MDR-TB) with the possibility of quick adoption in a resource limited setting is urgently required. We conducted a study combining isoniazid and rifampicin in a single LJ medium, to detect MDR-TB strains. Combined and...

  • Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis - An Update. Basso, L. A.; Santos, D. S. // Medicinal Chemistry Reviews - Online;Oct2005, Vol. 2 Issue 5, p393 

    Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis, and infects approximately 32 % of the world's human population. It is estimated that 8.2 million new TB cases occurred worldwide in the year 2000, with approximately 1.8 million...

  • Status epilepticus due to attempted suicide with isoniazid. Tibussek, Daniel; Mayatepek, Ertan; Distelmaier, Felix; Rosenbaum, Thorsten // European Journal of Pediatrics;Feb2006, Vol. 165 Issue 2, p136 

    The article presents a case of a female adolescent with intentional isoniazid overdosage resulting in status epilepticus and encephalitis-like signs and symptoms. A 10-year-old girl presented with noisy, irregular breathing during night sleep. She also had prolonged generalised tonic-clonic...

  • Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig. Spector, Stephen A. // Journal of Infectious Diseases;10/1/2009, Vol. 200 Issue 7, p1136 

    The article presents a research study on the anti tuberculosis (TB) activity of isoniazid and its ability to select for drug-resistant mutant strains in guinea pigs, in which the histopathology of TB closely resembles that of human TB. In this study, researchers developed a guinea pig model of...

  • Gatifloxacin in combination with rifampicin in a murine tuberculosis model. Michael Cynamon; Mary R. Sklaney; Carolyn Shoen // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p429 

    Objectives Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis. Several regimens of gatifloxacin in combination with rifampicin were compared with isoniazid plus rifampicin in a mouse tuberculosis model. Methods C57BL/6 mice were infected...

  • CHIH-DFT determination of the molecular structure infrared spectra, UV spectra and chemical reactivity of three antitubercular compounds: Rifampicin, Isoniazid and Pyrazinamide. Alejandra Favila; Marco Gallo; Daniel Glossman-Mitnik // Journal of Molecular Modeling;Apr2007, Vol. 13 Issue 4, p505 

    Abstract??Three of the most frequent antitubercular agents employed against Mycobacterium tuberculosis are: Rifampicin, Isoniazid and Pyrazinamide. It has been proven that the use of these antitubercular agents together, shortens the treatment period from 12?18?months to 6?months...

  • The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic Complex. Vasconcelos, I. B.; Meyer, E.; Sales, F. A. M.; Moreira, I. S.; Basso, L. A.; Santos, D. S. // Anti-Infective Agents in Medicinal Chemistry;2008, Vol. 7 Issue 1, p50 

    Tuberculosis (TB) remains the leading cause of mortality due to a single bacterial pathogen, Mycobacterium tuberculosis. The reemergence of tuberculosis as a potential public health threat, the high susceptibility of human immunodeficiency virus-infected persons to the disease, the proliferation...

  • Isoniazid and Liver Disease.  // Clinical Pediatrics;Feb1972, Vol. 11 Issue 2, p68 

    Provides information on the medicine isoniazid (INH) for treatment of tuberculosis which is been associated to cause liver damage with its use in the U.S. Percentage of cases cited; Suggestions that use of INH-associated liver disease does not appear to occur in children; Recommendations by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics